2018 Volume 69 Issue 1 Pages 1-6
Glasgow prognostic score (GPS) has been found to relate to poor prognosis in several kinds of solid carcinoma, including esophageal cancer. However, its role in esophageal cancer with recurrent diseases (ER) is unclear. This study aimed to clarify the prognostic value of the modified GPS (mGPS) in ER patients. A total of 52 ER patients who underwent radical esophagectomy between April 2010 and December 2016 were enrolled in this study. The mGPS was measured when the recurrent diseases were diagnosed. The relationship between mGPS and clinicopathological factors, including survival time, was analyzed. The mGPS was classified as mGPS 0 in 31 patients, and mGPS 1 or 2 in 21 patients. The mGPS 1 and 2 group was associated with complex recurrence (p<0.05) and symptoms at recurrence (p<0.05). The median survival time after recurrence in all cases was 293 days, and that of mGPS 1 or 2 patients was significantly worse than that of mGPS 0 patients. Elevation of mGPS with recurrent esophageal cancer was associated with systemic spread of recurrent diseases, and was an independent poor prognosis factor for patients with recurrent diseases after radical esophagectomy.
